GTC presented abstracts at ASH 2024
GTC’s posters from 2024 Convention of American Society of Hematology are now available to be downloaded. Please reach out with any questions.
Establishing a Distinct Cytokine Signature for Multiple Myeloma
Using Bone Marrow RNA and Peripheral Blood Cell-Free RNA (cfRNA)
Establishing Distinct Cytokine Signatures Differentiating between Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Chip Using Bone Marrow RNA or Cell-Free RNA (cfRNA)
Establishing Lymphoma Type-Specific Cytokine Signatures
Using Tissue-Based RNA or Peripheral Blood Cell-Free RNA (cfRNA)
Clonotype- naive Detection Of Clonality in Patients Suspected of Having Multiple Myeloma or Monoclonal Gammopathy Using Peripheral Blood Cell-Free RNA (cfRNA)
Read more Articles and News from GTC
Summit Health Announces Internalization of GTC’s DNA & RNA Profiling Tests
Summit Health Announces Internalization of GTC’s State-of-The-Art Next Gen Sequencing DNA & RNA Profiling Tests for Tissue and Liquid Biopsy of Solid Tumors and Hematologic
GTC featured in OC Business Journal
GTC Expands Cancer Tests to Europe via Partnership By Yuika Yoshida April 7, 2025 Genomic Testing Cooperative (GTC) is expanding into the European market by partnering with
Genomic Testing Cooperative Receives UKCA Mark for its Portfolio of Hematology, Solid Tumors and Liquid Biopsy Profiles covering DNA and RNA
Lake Forest, CA – April 8, 2025 – Genomic Testing Cooperative (GTC) today announced it received UKCA marks for its Hematology Profile Plus, Solid Tumor
Labor Dr. Wisplinghoff and Genomic Testing Cooperative (GTC) Partner to Deploy GTC’s Comprehensive Suite of Tissue and Liquid Biopsy Testing for Solid Tumor and Hematologic Neoplasms in Germany
Cologne, Germany and Lake Forest, CA. USA, March 18, 2025 – Labor Dr. Wisplinghoff one of Germanys largest and most renowned medical laboratories and Genomic
mRNA Expression in DLBCL Patients who are CD20 Dim With an Eye Towards More Thoughtful Design of R/R Trials, Possibly Incorporating BCMA Bite Therapy
Bruce Hough, Maher Albitar Clinical Lymphoma, Myeloma and Leukemia, Vol. 000, No.xxx, 1–3 © 2025 Published by Elsevier Inc. Keywords: CD19 dim, Diffuse large b-cell
Next‑generation sequencing (NGS) detects presence of chimeric antigen receptor (CAR) T‑cell construct in a diffuse large B‑cell lymphoma patient with no response to CAR T‑cell therapy: a case report
Aishwarya Sridhar1 · Dylon Patel1 · Alexandra Della Pia2 · Tatyana A. Feldman2,3 · Lori A. Leslie2,3 · Andre H. Goy1,2 · Maher Albitar4 · Andrew Ip2,3Received: 27 June 2024 / Accepted: 19 November 2024© The Author(s) 2024 OPEN AbstractBackground CD19-directed chimeric antigen receptor